Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,622 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Zhang L, et al. Among authors: gray h. N Engl J Med. 2003 Jan 16;348(3):203-13. doi: 10.1056/NEJMoa020177. N Engl J Med. 2003. PMID: 12529460 Free article.
Ovarian cancer, version 2.2013.
Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M; National comprehensive cancer networks. Morgan RJ Jr, et al. J Natl Compr Canc Netw. 2013 Oct 1;11(10):1199-209. doi: 10.6004/jnccn.2013.0142. J Natl Compr Canc Netw. 2013. PMID: 24142821
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, Fujiwara K, Alberts DS, Zheng W, Tewari KS, Cohn DE, Powell MA, Van Le L, Davidson SA, Gray HJ, Rose PG, Aghajanian C, Myers T, Alvarez Secord A, Rubin SC, Mannel RS. Walker JL, et al. J Clin Oncol. 2019 Jun 1;37(16):1380-1390. doi: 10.1200/JCO.18.01568. Epub 2019 Apr 19. J Clin Oncol. 2019. PMID: 31002578 Free PMC article. Clinical Trial.
Epithelial ovarian cancer.
Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL; National Comprehensive Cancer Network. Morgan RJ Jr, et al. J Natl Compr Canc Netw. 2011 Jan;9(1):82-113. doi: 10.6004/jnccn.2011.0008. J Natl Compr Canc Netw. 2011. PMID: 21233246 No abstract available.
Ovarian cancer, version 3.2012.
Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA; National Comprehensive Cancer Network. Morgan RJ Jr, et al. Among authors: gray h. J Natl Compr Canc Netw. 2012 Nov 1;10(11):1339-49. doi: 10.6004/jnccn.2012.0140. J Natl Compr Canc Netw. 2012. PMID: 23138163
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. Coleman RL, et al. Gynecol Oncol. 2015 Jun;137(3):386-91. doi: 10.1016/j.ygyno.2015.03.042. Epub 2015 Mar 24. Gynecol Oncol. 2015. PMID: 25818403 Free PMC article. Clinical Trial.
1,622 results